231 related articles for article (PubMed ID: 21321296)
1. Use of bisphosphonates and reduced risk of colorectal cancer.
Rennert G; Pinchev M; Rennert HS; Gruber SB
J Clin Oncol; 2011 Mar; 29(9):1146-50. PubMed ID: 21321296
[TBL] [Abstract][Full Text] [Related]
2. Use of bisphosphonates and risk of postmenopausal breast cancer.
Rennert G; Pinchev M; Rennert HS
J Clin Oncol; 2010 Aug; 28(22):3577-81. PubMed ID: 20567021
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
4. The effect of bisphosphonates on the risk of endometrial and ovarian malignancies.
Rennert G; Rennert HS; Pinchev M; Lavie O
Gynecol Oncol; 2014 May; 133(2):309-13. PubMed ID: 24556062
[TBL] [Abstract][Full Text] [Related]
5. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
7. Risk of colorectal cancer in users of bisphosphonates: analysis of population-based electronic health records.
Ibáñez-Sanz G; Guinó E; Pontes C; Morros R; de la Peña-Negro LC; Quijada-Manuitt MÁ; Moreno V
Eur J Epidemiol; 2020 Jan; 35(1):37-48. PubMed ID: 31734885
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
9. Use of hormone replacement therapy and the risk of colorectal cancer.
Rennert G; Rennert HS; Pinchev M; Lavie O; Gruber SB
J Clin Oncol; 2009 Sep; 27(27):4542-7. PubMed ID: 19704062
[TBL] [Abstract][Full Text] [Related]
10. The effect of statins on risk and survival of gynecological malignancies.
Lavie O; Pinchev M; Rennert HS; Segev Y; Rennert G
Gynecol Oncol; 2013 Sep; 130(3):615-9. PubMed ID: 23718932
[TBL] [Abstract][Full Text] [Related]
11. [Bisphosphonates: less colon carcinomas].
Orthopade; 2013 Jun; 42(6):454. PubMed ID: 23862188
[No Abstract] [Full Text] [Related]
12. [Bisphosphonates and breast cancer].
Vehmanen L; Saarto T
Duodecim; 2010; 126(10):1229-37. PubMed ID: 20597352
[TBL] [Abstract][Full Text] [Related]
13. Oral Bisphosphonates and Improved Survival of Breast Cancer.
Rennert G; Pinchev M; Gronich N; Saliba W; Flugelman A; Lavi I; Goldberg H; Fried G; Steiner M; Bitterman A; Landsman K; Rennert HS
Clin Cancer Res; 2017 Apr; 23(7):1684-1689. PubMed ID: 27683176
[No Abstract] [Full Text] [Related]
14. [Current use of bisphosphonates in clinical oncology].
Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature.
Liu Y; Zhao S; Chen W; Hu F; Zhu L; Zhang Q; Zhao Y
Clin Breast Cancer; 2012 Aug; 12(4):276-81. PubMed ID: 22622199
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates for advanced prostate cancer.
Yuen KK; Shelley M; Sze WM; Wilt T; Mason MD
Cochrane Database Syst Rev; 2006 Oct; (4):CD006250. PubMed ID: 17054286
[TBL] [Abstract][Full Text] [Related]
17. Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience.
Enright K; Clemons M; Chow E
Support Care Cancer; 2004 Jan; 12(1):48-52. PubMed ID: 14577020
[TBL] [Abstract][Full Text] [Related]
18. Statins and the risk of colorectal cancer.
Poynter JN; Gruber SB; Higgins PD; Almog R; Bonner JD; Rennert HS; Low M; Greenson JK; Rennert G
N Engl J Med; 2005 May; 352(21):2184-92. PubMed ID: 15917383
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefit.
Bal O; Oksuzoglu B; Dogan M; Durnali A; Uyeturk U; Demirci A; Arslan UY; Ekinci AS; Yildirim N; Alkis N; Kilic S
Ir J Med Sci; 2020 Aug; 189(3):805-810. PubMed ID: 31823174
[TBL] [Abstract][Full Text] [Related]
20. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
Lipton A
Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
